Chacko Shinu, Samanta Subir
Division of Pharmaceutical Chemistry, Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi, Jharkhand 835215, India.
Division of Pharmaceutical Chemistry, Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi, Jharkhand 835215, India.
Biomed Pharmacother. 2016 Dec;84:1679-1688. doi: 10.1016/j.biopha.2016.10.078. Epub 2016 Nov 4.
An estimated rise in liver cancer incidence will increase to 95374 new cases by 2020. Hepatocellular Carcinoma (HCC), the most common primary malignant tumour of the liver, is considered to be the third leading cause of all cancer-related deaths and fifth common cancer worldwide. The reported data shows that the rate of HCC incidence in male population is three to four times higher compared with the female population. In the United States, HCV-induced liver cancer is increasing very fast because of the lack of proper treatment option. There are various treatment strategies available for HCC like liver transplantation, resection, ablation, embolization and chemotherapy still the prognosis is destitute. If the patient is eligible, liver transplantation is the only therapeutic option that may give around 90% survival rate, but the scarcity of liver donor limits its broad applicability. A sudden address is necessary to develop specific drugs, personalized medicine, for HCC.
据估计，到2020年肝癌发病率将上升至95374例新发病例。肝细胞癌（HCC）是肝脏最常见的原发性恶性肿瘤，被认为是全球所有癌症相关死亡的第三大主要原因和第五大常见癌症。报告数据显示，男性人群中HCC的发病率是女性人群的三到四倍。在美国，由于缺乏适当的治疗选择，丙型肝炎病毒（HCV）诱发的肝癌正在迅速增加。HCC有多种治疗策略，如肝移植、切除、消融、栓塞和化疗，但预后仍然很差。如果患者符合条件，肝移植是唯一可能提供约90%生存率的治疗选择，但肝脏供体的稀缺限制了其广泛应用。迫切需要开发针对HCC的特异性药物，即个性化药物。
